Shifting the Paradigm: Noncontrast MRI-First Screening Strategy Significantly Increases Detection of Clinically Significant Prostate Cancer
The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and benefit-harm ratios.
